Drugs / IC84
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01296386 | Dec 2010 → Apr 2013 | Clostridium difficile colitis | Valneva Austria GmbH | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IC84 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01296386 ↗ |
| Known as | VLA84 | “Safety, immunogenicity and dose response of VLA84” PMID 27079932 ↗ Apr 2016 |
| Modality | Vaccine | “a new vaccine against Clostridium Difficile” NCT01296386 ↗ |
| Route | Intramuscular | “intramuscular (i.m.) injection” NCT01296386 ↗ |